BELLUS Health Inc. (BLU)
Stock Price:
$2.71 USD
0.06 (2.26%)
Updated Aug 4, 2020 4:00 PM EDT - Market closed
After-hours: $2.70 -0.01 (-0.37%) Aug 4, 7:44 PM
Key Info
| Market Cap |
163.38M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
n/a |
| Shares Out |
60.25M |
| EPS (ttm) |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 4, 2020 |
| Last Price |
$2.71 |
| Previous Close |
$2.65 |
| Change ($) |
0.06 |
| Change (%) |
2.26% |
| Day's Open |
2.60 |
| Day's Range |
2.60 - 2.77 |
| Day's Volume |
2,668,390 |
| 52-Week Range |
2.30 - 12.03 |
More Stats
| Market Cap |
163.38M |
| Enterprise Value |
109.65M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
60.25M |
| Float |
34.44M |
| EPS (basic) |
n/a |
| EPS (diluted) |
n/a |
| FCF / Share |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
1.60M |
| Short Ratio |
0.44 |
| Short % of Float |
n/a |
| Beta |
-0.21 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
1.25 |
| Revenue |
n/a |
| Operating Income |
n/a |
| Net Income |
n/a |
| Free Cash Flow |
n/a |
| Net Cash |
53.73M |
| Net Cash / Share |
0.89 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-22.03% |
| ROE |
-38.21% |
| ROIC |
n/a |
Key stats in USD, based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (8)
| Buy |
4 |
| Overweight |
1 |
| Hold |
3 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$9.73*
(259.04% upside)
Low
5.00
Current: $2.71
High
28.00
Target: 9.73
*Average 12-month USD price target from 6 stock analysts.
Financial Performance
Financial numbers in millions cad.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 |
|---|
| Revenue | 0.04 | 0.04 | 0.17 | 0.72 | 1.52 | 2.82 | 3.67 | 0.33 | - |
| Revenue Growth | 0% | -78.79% | -76.92% | -52.81% | -46.24% | -23.11% | 1020.8% | - | - |
| Gross Profit | 0.04 | 0.04 | 0.17 | 0.72 | 1.52 | 2.82 | 3.67 | 0.33 | - |
| Operating Income | -34.10 | -9.91 | -5.69 | -61.92 | -84.76 | -67.84 | -60.18 | -54.74 | -15.50 |
| Net Income | -34.47 | -9.08 | -1.87 | -59.03 | -81.49 | -66.47 | -59.73 | -52.40 | -16.77 |
| Shares Outstanding | 55.38 | 0.46 | 0.46 | 0.46 | 0.45 | 0.36 | 0.35 | 0.28 | 0.27 |
| Earnings Per Share | -0.73 | -0.27 | -0.11 | -128.53 | -199.82 | -185.78 | -183.62 | -187.94 | -68.05 |
| Operating Cash Flow | -27.87 | -10.17 | -4.36 | - | -66.05 | -54.92 | -55.25 | -43.04 | -16.52 |
| Capital Expenditures | - | - | - | -0.24 | -0.58 | -0.80 | -1.07 | -14.72 | -0.92 |
| Free Cash Flow | -27.87 | -10.17 | -4.36 | - | -66.63 | -55.72 | -56.32 | -57.76 | -17.43 |
| Cash & Equivalents | 89.98 | 35.86 | 23.89 | 11.19 | 64.14 | 55.31 | 78.73 | 29.17 | 77.59 |
| Total Debt | 0.19 | 0.11 | 0.02 | 47.20 | 35.42 | 33.65 | - | 10.55 | 0.84 |
| Net Cash / Debt | 89.79 | 35.75 | 23.87 | -36.01 | 28.72 | 21.66 | 78.73 | 18.62 | 76.75 |
| Assets | 96.37 | 39.20 | 28.50 | 26.42 | 78.43 | 71.40 | 96.95 | 76.45 | 94.23 |
| Liabilities | 7.63 | 2.11 | 2.21 | 72.47 | 74.52 | 73.12 | 46.67 | 35.75 | 6.66 |
| Book Value | 88.74 | 37.09 | 26.29 | -46.05 | 3.23 | -2.44 | 49.76 | 40.69 | 87.57 |
Numbers in millions cad, except per-share numbers.
Company Details
| Full Name |
BELLUS Health Inc. |
| Country |
Canada |
| Employees |
17 |
| CEO |
Roberto Bellini |
Stock Information
| Ticker Symbol |
BLU |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: BLU |
Description
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of chronic cough and other hypersensitization disorders. Its lead drug candidate includes BLU-5937, an oral small molecule antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of chronic cough and chronic pruritus. BELLUS Health Inc. was founded in 1993 and is headquartered in Laval, Canada.